The limited capacity for repair in the nervous system represents a significant medical challenge: as such, we wanted to explore the current status of the field of neuroregeneration in our latest Spotlight. What is the potential for regeneration in the nervous system? How can this be harnessed to treat neurological disease? And how far have we come in a relatively new research field?
Along with leaders in the field, we’ll explore the latest clinical trials, research pipelines and new treatments across neurology and neuroscience, taking a look at recent successes, hurdles and future directions. Topics will include stem cell transplantation in Parkinson’s disease, spinal cord repair trials and remyelination in multiple sclerosis, which will be covered through a series of interviews, videos, opinion pieces and journal articles, including from the award-winning journal, Regenerative Medicine.
In this review, the authors discuss the challenges associated with neural regeneration and review the progress of stem cell-based regenerative medicine.
Preliminary findings suggest that some cell therapies may be relatively safe and effective, but larger double-blinded placebo-controlled studies are needed to establish the long-term risks and benefits.
Cedric Bardy discusses progresses in stem cell reprogramming technologies that have the potential to lead to the discovery of new clinical treatments for neurological and psychiatric disorders.
Curt Freed discusses his pioneering work on transplanting human fetal dopaminergic cells, and where Parkinson’s disease research and treatment is heading in the next decade.
A group of researchers report the intrinsic role of spindle matrix proteins in regulating neural stem cell reactivation and proliferation. The findings could contribute to the development of stem cell-based therapies for neurological disorders.
Researchers discover latent human herpes virus 6 may interfere with the brains ability to repair damaged myelin in brain diseases such as multiple sclerosis.
The randomized, placebo-controlled Phase I-II clinical study will investigate CDNF delivered with Renishaw’s chronic drug delivery system in Parkinson’s disease patients.
Researcher have developed a compound, P7C3-A20, which not only prevents mature neurons dying during stroke, but also encourages neurogenesis after a stroke to protect cognitive function.
Autologous hematopoietic stem cell transplantation prevented symptoms of severe MS from worsening for 5 years in 46% of patients in a recent clinical trial.
A new study suggests the possibility of the regrowth of dopaminergic neurons in adult mammals, which could lead to a new treatment avenue for Parkinson’s disease.
Researchers have found that the vitamin D receptor promotes the differentiation of oligodendrocyte progenitor cells and enhances myelin sheath regeneration.
